Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity

British Journal of Haematology

Volumn 97, Issue 3, 1997, Pages 641-648

  Diamond, T ^a   Levy, S ^a   Day, P ^a   Barbagallo, S ^a   Manoharan, A ^a   Kwan, Y K ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

bone density; multiple myeloma; osteoporosis

Indexed keywords

GLUCOCORTICOID;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DENSITOMETRY; HUMAN; MORPHOMETRICS; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0030975520     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.1042920.x     Document Type: Article

References (31)

1. Abilgaard, N., Nirlsen, J.L. & Heickendorff, L. (1994) Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. American Journal of Hematology, 46, 173-178.
2. Alexanian, R. & Dreicer, R. (1984) Chemotherapy for multiple myeloma. Cancer, 53, 533-538.
3. Bataille, R., Chappard, D., Alexandre, C., Dessauw, P. & Sany, J. (1986) Importance of quantitative histology of bone in monoclonal gammopathy. British Journal of Cancer, 53, 805-810.
4. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J. & Alexandre, C. (1992) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. Journal of Clinical Investigation, 88, 62-66.
5. Bataille, R., Delmas, P.D., Chappard, D. & Sany, J. (1987) Serum bone Gla-protein in multiple myeloma. Cancer, 59, 329-334.
6. Bataille, R., Delmas, P.D., Chappard, D., Sany, J. & Alexandre, C. (1990) Prognostic implications of serum bone Gla-protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer, 66, 167-172.
7. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R.D., for the Myeloma Aredia Study Group (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488-493
8. Bressot, C., Meunier, P.J., Chapuy, M.C., Lejeune, E., Edouard, C. & Darby, A.Y. (1978) Histomorphometric profile, pathophysiology and reversibility of glucocorticoid induced osteoporosis. Metabolic Bone Diseases and Related Research, 1, 303-311.
9. Diamond, T., McGuigan, L., Barbagallo, S. & Bryant, C. (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. American Journal of Medicine, 98, 459-463.
10. Diamond, T.H., Stiel, D., Lunzer, M., McDowall, D., Eckstein, R.P. & Posen, S. (1989) Hepatic osteodystrophy: static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology, 96, 213-221.
11. Dunbar, C.E. & Nienhuis, A.W. (1983) Multiple myeloma: new approaches to therapy. Journal of the American Medical Association, 269, 2412-2416.
12. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival, Cancer, 36, 842-854.
13. Durie, B.G.M., Salmon, S.E. & Mundy, G.R. (1981) Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. British Journal of Haematology, 47, 21-30.
14. Elomaa, I., Virkkunen, P., Risteli, L. & Risteli, J. (1992) Serum concentrations of the cross-linked carboxyterminal telopepetide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. British Journal of Cancer, 66, 337-341.
15. Jantunen, E. & Laakso, M (1996) Bisphosphonates in multiple myeloma: current status, future perspectives. British Journal of Haematology, 93, 501-506.
16. Klein, B., Zhang, X.G. & Jourdan, M. (1990) Interleukin-6 is the central tumour growth factor in vitro and in vivo in multiple myeloma. European Cytokine Network, 1, 193-201.
17. Kyle, R.A. (1975) Multiple myeloma: a review of 869 cases. Mayo Clinic Proceedings, 50, 29-40.
18. Larnach, T.A., Boyd, S.J., Smart, R.C., Butler, S.P., Rohl, P.G. & Diamond, T.H. (1992) Reproducibility of lateral spine scans using dual energy X-ray absorptiomerry. Calcified Tissue International, 51, 255-258.
19. Laroche, M., Pouilles, J.M., Dromer, C., Attal, M. & Ribot, C. (1996) Dual energy X-ray absorptiometry in patients with multiple myeloma and benign gammopathies. Clinical and Experimental Rheumatology, 14, 108.
20. Mariette, X., Bergot, C., Ravaud, P., Roux, C., Laval-Jeantet, M., Brouet, J.C. & Fermand, J.P. (1985) Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer, 76, 1559-1563.
21. Mariette, X., Khalifa, P., Ravaud, P., Frija, J., Laval-Jeantet, M., Chastang, C., Brouet, J.C. & Fermand, J.P. (1992) Bone densitometry in patients with multiple myeloma. American Journal of Medicine, 93, 595-598.
22. Mundy, G.R. & Bertolini, D.R. (1986) Bone destruction and hypercalcemia in plasma cell myeloma. Seminars in Oncology, 13, 291-299.
23. Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M. & Recker, R.R. (1987) Bone histomorphometry: standardization of nomenclature, symbols and units. Journal of Bone and Mineral Research, 2, 595-610.
24. Peest, D., Blade, J. & Harousseau, J.L. (1996) Cytokine therapy in multiple myeloma. British Journal of Haematology, 94, 425-432.
25. Reid, I. (1989) Pathogenesis and treatment of steroid osteoporosis. Clinical Endocrinology, 4, 137-141.
26. Reid, I. & Heap, S.W. (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Archives of Internal Medicine, 150, 2545-2548.
27. Roodman, G.D. (1995) Osteoclast function in Paget's disease and multiple myeloma. Bone, 17, (Suppl. 2), 57S-61S.
28. Roux, C., Ravaud, P., Cohen-Solal, M., De Vernejoul, M.C., Guillemant, S., Cherruau, B., Delmas, P., Dougados, M. & Amor, B. (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone, 15, 41-49.
29. Sato, M., Grasser, W., Endo, N., Akins, R., Simmond, H., Thompson, D.D. & Rodan, G.D. (1991) Bisphosphonate action: alendronate localisation in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investiaation, 88, 2095-2105.
30. Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers, S., Greaves, M. & Kanis, J.A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resoprtion. European Journal of Haematology, 49, 192-198.
31. Valentin-Opran, A., Charhon, S.A., Meunier, P.J., Edouard, C.M. & Arlot, M.E. (1982) Quantitative histology of myeloma-induced bone changes. British Journal of Haematology, 52, 601-610.